MS 073
Alternative Names: CP 117227Latest Information Update: 31 Aug 2007
At a glance
- Originator Nihon Schering; Pfizer
- Developer Nihon Schering
- Class Antineoplastics; Radiosensitisers
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer